Literature DB >> 24650262

The Relationship Between Neurocognitive Behavior of Executive Functions and the EFPT in Individuals with Multiple Sclerosis.

Gerald T Voelbel, Yael Goverover, Elizabeth A Gaudino, Nancy B Moore, Nancy Chiaravalloti, John Deluca.   

Abstract

The current study examined the relationship between two separate but complementary methods of assessing executive functions in individuals with multiple sclerosis (MS): (1) a neurocognitive approach with the Tower of London(-DX) (TOL-DX) test and (2) a functional top-down approach with the Executive Function Performance Test (EFPT). Sixty-eight individuals with MS (79% female) and 38 healthy controls (68% female) were administered both the TOL-DX test and the EFPT. For the group with MS, significant differences were found on the TOL-DX test and the EFPT executive components and functional tasks. For the group with MS, the number of moves to complete the TOL-DX tasks was significantly positively correlated to the Organization and Sequencing executive components of the EFPT and the Simple Cooking and Bill Payment tasks of the EFPT. The results demonstrate the relationship of executive function behavior and performance of instrumental activities of daily living tasks. Copyright 2011, SLACK Incorporated.

Entities:  

Year:  2011        PMID: 24650262     DOI: 10.3928/15394492-20101108-06

Source DB:  PubMed          Journal:  OTJR (Thorofare N J)        ISSN: 1539-4492


  3 in total

1.  Introduction: cognitive dysfunction in multiple sclerosis.

Authors:  Ralph H B Benedict; Kathleen Fuchs
Journal:  Int J MS Care       Date:  2012

2.  D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive Disability.

Authors:  Alice Riccardi; Marco Puthenparampil; Francesca Rinaldi; Mario Ermani; Paola Perini; Paolo Gallo
Journal:  Front Psychol       Date:  2019-01-24

Review 3.  Treatment and management of cognitive dysfunction in patients with multiple sclerosis.

Authors:  John DeLuca; Nancy D Chiaravalloti; Brian M Sandroff
Journal:  Nat Rev Neurol       Date:  2020-05-05       Impact factor: 42.937

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.